LMX1A: A Protein Target for Neurological Disorders (G4009)
LMX1A: A Protein Target for Neurological Disorders
LMX1A (LMX-1.1), a protein that belongs to the family of linear motif-binding proteins (LMX), is a key regulator of neural development, plasticity, and memory. LMX1A has been identified as a potential drug target and biomarker for Various neurological and psychiatric disorders, including Alzheimer's disease, Parkinson's disease, and depression.
The LMX family of proteins consists of four isoforms: LMX1A, LMX1B, LMX2A, and LMX3A. LMX1A is the most well-studied isoform and is widely expressed in various tissues, including brain, heart, and muscle. LMX1A is a 21-kDa protein that contains 11 transmembrane domains and a N-terminus that is involved in its stability and interactions with other proteins.
LMX1A functions as a negative regulator of microtubule dynamics and stability. Microtubules are dynamic organelles that play a crucial role in cell division, intracellular transport, and signaling. LMX1A is known to regulate the stability of microtubules by interacting with the protein tau, which is a key component of microtubules. LMX1A has been shown to physically interact with tau and to regulate its stability.
LMX1A's role in neural development and plasticity is multifaceted. LMX1A is involved in the regulation of neuronal differentiation and plasticity, as well as in the maintenance of neuronal survival. LMX1A has been shown to play a role in the development and progression of various neurological disorders, including Alzheimer's disease and Parkinson's disease.
In addition to its role in neurological development and plasticity, LMX1A is also a potential biomarker for various psychiatric disorders. LMX1A has been shown to be abnormally expressed in the brains of individuals with Alzheimer's disease and to be involved in the development of frontotemporal dementia. LMX1A has also been shown to be involved in the regulation of mood and anxiety, which are symptoms of depression.
LMX1A's role in disease is also related to its potential as a drug target. LMX1A has also been shown to be involved in a variety of cellular processes that are important for disease development, including neurodegeneration, neuroinflammation, and stress. with several protein kinases, including Src/FAK and TrkB/MAPK, which are involved in neurodegeneration and stress responses.
LMX1A has also been shown to interact with several drugs that are currently being used to treat neurological and psychiatric disorders, including anti-inflammatory drugs, antidepressants, and neuroprotective agents. These drugs act by modulating various cellular processes that are involved in neurodegeneration and stress responses . However, the exact mechanisms by which these drugs interact with LMX1A are not well understood.
In conclusion, LMX1A is a protein that is involved in a variety of cellular processes that are important for neural development and plasticity. LMX1A has been identified as a potential drug target and biomarker for a variety of neurological and psychiatric disorders, including Alzheimer's disease, Parkinson's disease, and depression. Further research is needed to fully understand the role of LMX1A in disease and to develop effective treatments.
Protein Name: LIM Homeobox Transcription Factor 1 Alpha
Functions: Acts as a transcriptional activator by binding to an A/T-rich sequence, the FLAT element, in the insulin gene promoter. Required for development of the roof plate and, in turn, for specification of dorsal cell fates in the CNS and developing vertebrae (By similarity)
The "LMX1A Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LMX1A comprehensively, including but not limited to:
• general information;
• protein structure and compound binding;
• protein biological mechanisms;
• its importance;
• the target screening and validation;
• expression level;
• disease relevance;
• drug resistance;
• related combination drugs;
• pharmacochemistry experiments;
• related patent analysis;
• advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai
More Common Targets
LMX1B | LMX1B-DT | LNC-LBCS | LNCAROD | LNCARSR | LNCATV | LNCNEF | LNCOC1 | LNCOG | LNCPRESS1 | LNCRI | LNCRNA-ATB | LNCRNA-IUR | LNCTAM34A | LNP1 | LNPEP | LNPK | LNX1 | LNX1-AS1 | LNX2 | LOC100127946 | LOC100127955 | LOC100128002 | LOC100128028 | LOC100128050 | LOC100128059 | LOC100128079 | LOC100128093 | LOC100128164 | LOC100128242 | LOC100128288 | LOC100128317 | LOC100128361 | LOC100128398 | LOC100128494 | LOC100128593 | LOC100128770 | LOC100128966 | LOC100128988 | LOC100129034 | LOC100129098 | LOC100129148 | LOC100129175 | LOC100129203 | LOC100129215 | LOC100129316 | LOC100129381 | LOC100129434 | LOC100129455 | LOC100129534 | LOC100129603 | LOC100129697 | LOC100130000 | LOC100130207 | LOC100130285 | LOC100130298 | LOC100130331 | LOC100130452 | LOC100130463 | LOC100130548 | LOC100130587 | LOC100130691 | LOC100130698 | LOC100130744 | LOC100130748 | LOC100130872 | LOC100130899 | LOC100130938 | LOC100130987 | LOC100130992 | LOC100131096 | LOC100131107 | LOC100131257 | LOC100131289 | LOC100131372 | LOC100131496 | LOC100131532 | LOC100131626 | LOC100131635 | LOC100131859 | LOC100131877 | LOC100131943 | LOC100132004 | LOC100132062 | LOC100132077 | LOC100132078 | LOC100132249 | LOC100132287 | LOC100132356 | LOC100132609 | LOC100132626 | LOC100132651 | LOC100132686 | LOC100132741 | LOC100132781 | LOC100132797 | LOC100133077 | LOC100133165 | LOC100133177 | LOC100133284
